US drug agency helps Medeva
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.THE United States Drug Enforcement Agency has given a helping hand to Medeva, the acquisitive pharmaceuticals group.
The company yesterday reported a surge in taxable profits from pounds 4m to pounds 14m for the half- year to 30 June on sales up from pounds 32m to pounds 58m.
Part of profits growth stemmed from a doubling of production quotas for one of Medeva's drugs used in curbing hyperactivity in children. Production of the drug, methylphenidate, is controlled by the DEA as it can be misused by adults as a stimulant. Medeva persuaded the DEA, which combats narcotics production and trafficking, to raise the limit, boosting underlying sales from the group's US operation by 80 per cent. Even so, most profits growth came from acquisitions.
However, Evan-Kerfoot, Medeva's generic products business, incurred a loss due to price cuts demanded by the Government. The company is by cutting jobs to improve its performance but will incur a pounds 1.5m restructuring charge in the second half.
Earnings doubled to 4.77p and the interim dividend is up from 0.5p to 0.75p.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments